To this day, a cure for cancer has yet to be discovered. But years of research have given us a better understanding of how ...

Fos, are integral to the brain's response to stimuli. Initially identified as a proto-oncogene, c-Fos is essential for neural ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

A promising new treatment to combat "undruggable" cancers has been green-lit for a human trial in 2025. It's hoped the novel ...

Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut health product, MastGut — a pioneering supplement that delivers ...

The Empowering Voices: Knowledge and Decision-Making Among People Impacted by Lung Cancer in Europe report, conducted by Lung Cancer Europe (LuCE) with the support of 40 member organisations, features ...

Necrosis drives aging and disease by triggering damaging inflammation. Interrupting it may offer new treatments for chronic ...

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...

Notably, it is in the kidneys that necrosis may have its most devastating and underappreciated impact. Necrosis induces ...

To date TT125-802 shows impressive anti-tumor activity in advanced solid tumors, including deep and durable responses in non-small cell lung cancer (NSCLC). In addition, TT125-802 demonstrates a ...

Despite the variety of treatments available for acute myeloid leukemia (AML), their therapeutic efficacy remains limited, and the 5-year survival rate is still below 30%. Epigenetic changes, including ...